Supplements

Fatigue in inflammatory rheumatic diseases frequently persists after clinically visible inflammation has improved, a mismatch termed the 'fatigue remission gap'.

This narrative review of evidence through July 2026 finds that fatigue in RA, SLE, and SjD is more strongly associated with pain, sleep disturbance, mood, and central pain sensitivity than with conventional inflammatory measures. In a 2026 RA cohort of 253 patients, 80% reported fatigue and 10% had severe fatigue, with fatigue present even in remission. The authors propose a treatable-traits framework to address this gap rather than escalating immunosuppression.

Last updated: Aug 12, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework.

observational

Gwóźdź-Broczkowska A · Rheumatology international (2026)

Participants: N/A
Duration: N/A
Intervention: Not applicable (narrative review); framework proposes sequential evaluation of disease activity, fatigue severity, pain/fibromyalgia overlap, sleep, mood, comorbidities, medication effects, and deconditioning.
Outcome: Fatigue severity, association with inflammatory markers, work and activity impairment, central pain sensitivity, brain imaging alterations.
Effect Size: N/A
Population: Patients with inflammatory rheumatic diseases (RA, SLE, Sjögren's disease), including a 253-patient RA cohort and an international survey of 1,155 people with SjD.

Result:

PubMed: 42565853DOI: 10.1007/s00296-026-06266-2

Mechanism Graph

Inflammation improves with treatment, but fatigue persists in many patients
↓
Fatigue is more strongly linked to non-inflammatory factors (pain, sleep, mood, central sensitization)
↓
Central pain sensitivity improvement tracks fatigue improvement in longitudinal RA data
↓
Result: Fatigue remission gap, requiring direct fatigue measurement and treatable-traits assessment

Limitations

  • ⚠Narrative review, not a systematic review or meta-analysis, so selection bias possible
  • ⚠No central or metabolic biomarker for fatigue is ready for routine use
  • ⚠Evidence for immune-targeted therapies on fatigue is variable and generally small-to-moderate

Frequently Asked Questions

Why does fatigue persist even when inflammation is controlled in rheumatic diseases?▼

Fatigue is more strongly associated with pain, sleep disturbance, mood symptoms, central pain sensitivity, and deconditioning than with conventional inflammatory markers, leading to a 'fatigue remission gap'.

What is the 'fatigue remission gap'?▼

It is the mismatch between inflammatory remission and continuing fatigue, a practical signal that should prompt direct fatigue measurement and a treatable-traits assessment rather than automatic escalation of immunosuppression.

What treatments are supported for fatigue in rheumatic diseases?▼

Personalized exercise, rehabilitation, cognitive-behavioural or self-management interventions, and treatment of sleep disorders have supportive clinical evidence, whereas immune-targeted therapies produce variable, generally small-to-moderate improvements.

How common is fatigue in rheumatic diseases?▼

In a 2026 RA cohort of 253 patients, 80% reported fatigue and 10% had severe fatigue. In an international survey of 1,155 people with SjD, physical fatigue was among the most frequent symptoms, with mean work and activity impairment of 46.6% and 48.4%.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Gwóźdź-Broczkowska A. "Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework.." Rheumatology international, 2026. PMID: 42565853 DOI: 10.1007/s00296-026-06266-2
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.